New hope for AML patients: targeted radiation combo trial launches
NCT ID NCT06802523
First seen Jan 07, 2026 · Last updated Apr 30, 2026 · Updated 18 times
Summary
This early-stage trial tests a new three-drug combination for adults newly diagnosed with acute myeloid leukemia (AML) who cannot have standard chemotherapy. The drugs include a targeted radiation therapy (lintuzumab-Ac-225), a pill that blocks cancer cell survival (venetoclax), and a two-drug combo (ASTX-727) that helps restore normal blood cell production. The study aims to find the safest doses and see if the combination improves remission rates. About 53 participants will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yale University Cancer Center LAO
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.